Pathy's Principles and Practice of Geriatric Medicine

28 28. Cohen HJ, Smith D, Sun CL, et al. Frailty as determined by a comprehensive geriatric assessment‐derived deficit‐accumulation index in older patients with cancer who receive chemotherapy. Cancer. 2016; 122(24):3865–3872. doi:10.1002/cncr.30269

29 29. Guerard EJ, Deal AM, Chang Y, et al. Frailty index developed from a cancer‐specific geriatric assessment and the association with mortality among older adults with cancer. JNCCN J Natl Compr Cancer Netw. 2017; 15(7):894–902. doi:10.6004/jnccn.2017.0122

30 30. Mohile SG, Dale W, Somerfield MR, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: Asco guideline for geriatric oncology. J Clin Oncol. 2018; 36(22):2326–2347. doi:10.1200/JCO.2018.78.8687

31 31. Abel GA, Hshieh TT, Condron NB, et al. Feasibility of Routine Frailty Screening Assessment for Patients in a Hematologic Oncology Clinic: Results from a Pilot Study. Blood. 2015; 126(23):3306–3306. doi:10.1182/blood.v126.23.3306.3306

32 32. Cesari M, Kritchevsky SB, Penninx BWHJ, et al. Prognostic value of usual gait speed in well‐functioning older people ‐ Results from the health, aging and body composition study. J Am Geriatr Soc. 2005; 53(10):1675–1680. doi:10.1111/j.1532‐5415.2005.53501.x

33 33. Cesari M, Kritchevsky SB, Newman AB, et al. Added value of physical performance measures in predicting adverse health‐related events: results from the Health, Aging And Body Composition Study. J Am Geriatr Soc. 2009; 57(2):251–259. doi:10.1111/j.1532‐5415.2008.02126.x

34 34. Studenski S, Perera S, Patel K, et al. Gait speed and survival in older adults. JAMA ‐ J Am Med Assoc. 2011; 305(1):50–58. doi:10.1001/jama.2010.1923

35 35. Mohile SG, Dale W, Somerfield MR, et al. Practical Assessment and Management of Vulnerabilities in Older Patients Receiving Chemotherapy: ASCO Guideline for Geriatric Oncology. J Clin Oncol. 2018; 36(22):2326–2347. doi:10.1200/JCO.2018.78.8687

36 36. Klepin HD, Geiger AM, Tooze JA, et al. Geriatric assessment predicts survival for older adults receiving induction chemotherapy for acute myelogenous leukemia. Blood. 2013; 121(21):4287–4294. doi:10.1182/blood‐2012‐12‐471680

37 37. Extermann M, Aapro M, Bernabei R, et al. Use of comprehensive geriatric assessment in older cancer patients: Recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005; 55(3):241–252. doi:10.1016/j.critrevonc.2005.06.003

38 38. Repetto L, Fratino L, Audisio RA, et al. Comprehensive Geriatric Assessment Adds Information to Eastern Cooperative Oncology Group Performance Status in Elderly Cancer Patients: An Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002; 20(2):494–502. doi:10.1200/JCO.2002.20.2.494

39 39. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998; 16(4):1582–1587. doi:10.1200/JCO.1998.16.4.1582

40 40. Hurria A, Togawa K, Mohile SG, et al. Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study. J Clin Oncol. 29:3457–3465. doi:10.1200/JCO.2011.34.7625

41 41. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007; 110(13):4385–4395. doi:10.1182/blood‐2007‐03‐082404

42 42. Heaney ML, Golde DW. Myelodysplasia. N Engl J Med. 1999; 340(21):1649–1660. doi:10.1056/NEJM199905273402107

43 43. Bernasconi P, Alessandrino EP, Boni M, et al. Karyotype in myelodysplastic syndromes: relations to morphology, clinical evolution, and survival. Am J Hematol. 1994; 46(4):270–277. doi:10.1002/ajh.2830460404

44 44. Hong M, He G. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes. J Transl Intern Med. 2017; 5(3):139–143. doi:10.1515/jtim‐2017‐0002

45 45. Genovese G, Kähler AK, Handsaker RE, et al. Clonal hematopoiesis and blood‐cancer risk inferred from blood DNA sequence. N Engl J Med. 2014; 371(26):2477–2487. doi:10.1056/NEJMoa1409405

46 46. Sanz‐De Pedro M, Wang W, Kanagal‐Shamanna R, Khoury JD. Myelodysplastic Syndromes: Laboratory Workup in the Context of New Concepts and Classification Criteria. Curr Hematol Malig Rep. 2018; 13(6):467–476. doi:10.1007/s11899‐018‐0483‐5

47 47. Cazzola M, Della Porta MG, Malcovati L. The genetic basis of myelodysplasia and its clinical relevance. Blood. 2013; 122(25):4021–4034. doi:10.1182/blood‐2013‐09‐381665

48 48. Tefferi A, Pardanani A, Lim KH, et al. TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis. Leukemia. 2009; 23(5):905–911. doi:10.1038/leu.2009.47

49 49. Delhommeau F, Dupont S, Della Valle V, et al. Mutation in TET2 in myeloid cancers. N Engl J Med. 2009; 360(22):2289–2301. doi:10.1056/NEJMoa0810069

50 50. Abdel‐Wahab O, Mullally A, Hedvat C, et al. Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies. Blood. 2009; 114(1):144–147. doi:10.1182/blood‐2009‐03‐210039

51 51. Itzykson R, Kosmider O, Cluzeau T, et al. Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias. Leukemia. 2011; 25(7):1147–1152. doi:10.1038/leu.2011.71

52 52. Malcovati L, Karimi M, Papaemmanuil E, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015; 126(2):233–241. doi:10.1182/blood‐2015‐03‐633537

53 53. Patnaik MM, Hanson CA, Sulai NH, et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization‐defined myelodysplastic syndromes without excess blasts. Blood. 2012; 119(24):5674–5677. doi:10.1182/blood‐2012‐03‐415356

54 54. Bejar R, Lord A, Stevenson K, et al. TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients. Blood. 2014; 124(17):2705–2712. doi:10.1182/blood‐2014‐06‐582809

55 55. Valent P, Horny H, Bennett JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes : Consensus statements and report from a working conference. 2007; 31:727–736. doi:10.1016/j.leukres.2006.11.009

56 56. Harris NL, Jaffe ES, Diebold J, et al. World health organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the clinical advisory committee meeting ‐ Airlie house, Virginia, November 1997. J Clin Oncol. 1999; 17(12):3835–3849. doi:10.1200/JCO.1999.17.12.3835

57 57. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016; 127(20):2391–2405. doi:10.1182/blood‐2016‐03‐643544

58 58. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: Rationale and important changes. Blood. 2009; 114(5):937–951. doi:10.1182/blood‐2009‐03‐209262

59 59. Greenberg PL, Stone RM, Al‐Kali A, et al. Myelodysplastic syndromes, version 2.2017: Clinical practice guidelines in oncology. JNCCN J Natl Compr Cancer Netw. 2017; 15(1):60–87. doi:10.6004/jnccn.2017.0007

60 60. Montalban‐Bravo G, Garcia‐Manero G. Myelodysplastic syndromes: 2018 update on diagnosis, risk‐stratification and management. Am J Hematol. 2018; 93(1):129–147. doi:10.1002/ajh.24930

61 61. Kantarjian H, O’Brien S, Ravandi F, et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer. 2008; 113(6):1351–1361. doi:10.1002/cncr.23697